Eli Lilly to present lung cancer studies at upcoming conference
INDIANAPOLIS A U.S. drug maker plans to present more than 30 lung cancer studies at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer in San Francisco.
Eli Lilly & Co. announced Monday that it would present data from studies involving drugs such as Alimta (pemetrexed), as a treatment for nonsquamous non-small cell lung cancer, and Gemzar (gemcitabine hydrochloride) at the conference, which takes place between Friday and Aug. 4.
“Our goal is, and always has been, to improve treatment options for individual patients,” Lilly VP cancer research Richard Gaynor said in a statement. “In lung cancer in particular, histology provides us with one way to tailor treatment with Alimta for patients living with nonsquamous NSCLC.”